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 Background Aberrant DNA methylation in gene promoters is associated with aging and cancer, but the circumstances deter-
mining methylation change are unknown. We investigated the impact of lifestyle modulators of colorectal cancer 
(CRC) risk on the stability of gene promoter methylation in the colonic mucosa.
 Methods We measured genome-wide promoter CpG methylation in normal colon biopsies (n = 1092) from a female screening 
cohort, investigated the interaction of lifestyle factors with age-dependent increase in methylation with log-linear mul-
tivariable regression, and related their modifying effect to hypermethylation in CRC. All statistical tests were two-sided.
 Results Of 20 025 promoter-associated CpGs analyzed, 1713 showed statistically significant age-dependent methylation 
gains. Fewer CpGs acquired methylation in users of aspirin (≥2 years) and hormonal replacement therapy (HRT 
age ≥50 years) compared with nonusers (43 vs 1355; 1 vs1377, respectively), whereas more CpGs were affected in 
smokers (≥20 years) and individuals with a body mass index (BMI) of 25 kg/m2 and greater compared with control 
groups (180 vs 39; 554 vs 144, respectively). Fifty percent of the CpGs showing age-dependent methylation were 
found hypermethylated in CRC (odds ratio [OR] = 20; 95% confidence interval [CI] = 18 to 23; P < 2 × 10–16). These 
loci gained methylation with a higher median rate compared with age-only methylated sites (P = 2 × 10–76) and 
were enriched for polycomb regions (OR = 3.67). Importantly, aspirin (P < .001) and HRT use (P < .001) reduced the 
methylation rate at these cancer-related genes, whereas smoking (P < .001) and high BMI (P = .004) increased it.
 Conclusions Lifestyle, including aspirin use, modulates age-associated DNA methylation change in the colonic epithelium and 
thereby impacts the evolution of cancer methylomes.
  JNCI J Natl Cancer Inst (2014) 106(7): dju161 doi:10.1093/jnci/dju161
Aberrations in DNA methylation deregulate the genome and 
contribute to the loss of tissue homeostasis observed in aging and 
diseases such as cancer (1,2). They can constitute both driver and 
passenger events of tumorigenesis, as evident from widespread 
changes in CpG methylation observed in cancers. Among those, 
the hypermethylation of promoter-associated CpG islands is a 
well-documented phenomenon (3), often associated with the loss 
of expression of the respective gene (4). Exactly why and how such 
epigenetic change arises is currently unknown.
Hypermethylation at promoters of tumor suppressor genes is a 
hallmark of colorectal cancer (CRC), for which age is a major risk fac-
tor (5,6). An increasing body of evidence indicates that aging is, at the 
same time, associated with an accumulation of aberrations in DNA 
methylation in human tissues, including colon (7–10). We and others 
have shown that de novo methylation at CpG island promoters of 
cancer-relevant genes arise in the aging mucosa of healthy individuals 
with no evidence of intestinal disease (11,12). Notably, these meth-
ylation changes appeared in patterns implicating a contribution of 
physiological and environmental factors (11,13,14). Understanding 
what controls the stability of DNA methylation in aging tissue is of 
both biological and clinical importance. Herein we address to what 
extent age-associated methylation change in the human colon is 
influenced by lifestyle and whether the ensuing epigenetic aberrations 
have relevance for neoplastic transformation. For this purpose, we 
determined CpG methylation levels in normal colon biopsies from 
a large female screening cohort and related these to the exposure of 
well-accepted CRC risk modulators (15–19): aspirin use, hormone 
replacement therapy (HRT), BMI, and smoking habits.
Methods
Study Participants and Data Collection
The study included 546 healthy women randomly recruited from 
a national colonoscopy screening for CRC in Poland (20). Ethical 
approval was obtained for all samples. From each participant, biop-
sies of normal mucosa from the cecum and sigmoid colon were 
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collected in RNAlater (Applied Biosystems, Lucerne, Switzerland) 
and stored at −80°C. Information on the use of aspirin, HRT, and 
cigarette smoking was collected using a self-administered question-
naire under the assistance of a study nurse (Table 1; Supplementary 
Materials, available online).
Quantification of DNA Methylation
Locus-Specific DNA Methylation. Bisulfite-converted genomic 
DNA of 1092 samples was used to measure human MutL homolog 
1 (hMLH1) and O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation levels (percentage of methylated 
alleles) by locus normalized quantitative methylation specific poly-
merase chain reaction (ln-qMSP). Full details are available in the 
Supplementary Materials (available online). Primer sequences are 
provided in the Supplementary Table 1.
Genome-Wide DNA Methylation. Genome-wide assessment of 
DNA methylation was done on Infinium HumanMethylation27 
Beadchip arrays (Illumina, San Diego, CA), interrogating methyla-
tion at 27 578 CpGs distributed in the promoters of 14 475 coding 
genes. Details on quantitation of methylation levels are available 
in the Supplementary Materials (available online). Microarray 
data were validated by bisulfite pyrosequencing (Supplementary 
Materials, available online).
All primary data generated in the study were deposited in the 
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/; accession No. GSE48988. Methylation data of 59 
female CRC samples were obtained from GEO (accession No. 
GSE25062) (21).
Gene Expression Analysis
Expression data for 32 colon adenomas/normal tissues were 
obtained from GEO (accession No. GSE8671) (22). The data were 
median normalized, log2 transformed, and analyzed using the R/
Bioconductor limma package.
H3K27me3 Status in Human Embryonic Stem Cells
H3K27me3 is a polycomb repressive mark of interest because 
its presence in stem cells has been shown to predispose genomic 
sequences to aberrant DNA methylation during aging and carcino-
genesis (8,23,24). An H3K27me3 profile in human embryonic stem 
cells was obtained from GSE13084 (25). Five hundred base-pair win-
dows symmetrically positioned around the Illumina Infinium human-
Methylation27 CpGs were analyzed for enrichment of H3K27me3.
Statistical Analyses
Locus-Specific DNA Methylation Analysis. Log-linear multivari-
able regression models were applied to investigate the interaction of 
age-related DNA methylation changes with lifestyle factors by con-
sidering age as a linear predictor and the four lifestyle factors of aspi-
rin use, HRT use, BMI, and smoking as categorical predictors. To 
analyze methylation interaction with age, corresponding interaction 
terms were introduced in the model. To investigate the interaction of 
age with polyps, separate multivariable regression models (adjusted 
for the interaction of the four lifestyle factors with age) were done by 
considering age as a linear predictor and polyps as categorical predic-
tors (either as one group [any polyp] or classified as tubular adenomas 
Table 1. Clinical characteristics of the study population
Characteristic
No. of 
subjects (%)
Age, y
 <60 275 (50)
 ≥ 60 271 (50)
Aspirin regular use*
 Nonuser† 391 (71)
 Short-term user (< 2y)‡ 86 (16)
 Long-term user (≥ 2y)§ 69 (19)
Hormone replacement therapy||
 Nonuser¶ 245 (45)
 Aged <50 y# 175 (32)
 Aged ≥ 50 y** 126 (23)
Body mass index, kg/m2††
 Normal, 18.5–25 227 (42)
 Overweight, 26–30 224 (41)
 Obese, >30 95 (17)
Cigarette smoking‡‡
 Nonsmoker§§ 272 (50)
 Short-term smoker, <20 y|||| 122 (22)
 Long-term smoker, ≥20 y¶¶ 152 (28)
Polyps
 No polyps 350 (64)
 Yes 196 (36)
  Proximal colon##
  Tubular adenoma 49 (25)
  Serrated lesion*** 25 (13)
   Hyperplastic polys 22 (11)
   Sessile serrated adenoma 3 (2)
  Distal colon†††
  Tubular adenoma 41 (21)
  Serrated lesion 81 (41)
   Hyperplastic polyps 69 (35)
   Sessile serrated adenoma 12 (6)
* Regular use defined as two or more tablets per week for 1 or more months.
† Non-user: women who indicated that they did not use two or more aspirin 
tablets per week for 1 or more months (minimum level).
‡ Short-term user: women who indicated that they used two or more aspirin 
tablets per week for less than 2 years.
§ Long-term user: women who indicated that they used two or more aspirin 
tablets per week for 2 or more years.
|| Hormone replacement therapy defined as estrogen therapy and/or oral 
contraceptive for 1 or more years.
¶ Non-user: women who indicated that they did not have hormone 
replacement therapy for 1 or more years (minimum level).
# Aged <50: women who indicated that they did had hormone replacement 
therapy for 1 or more years before age 50 years.
** Aged ≥50 years: women who indicated that they did have hormone 
replacement therapy for 1 or more years after the age of 50 years.
†† Body mass index: height (cm) and weight (kg) were self-reported, and body 
mass index was calculated (kg/m2) from these variables.
‡‡ Cigarette smoking was defined as one or more cigarettes per day for one or 
more years.
§§ Nonsmoker: women who indicated that they did not smoke one or more 
cigarettes per day for 1 or more years (minimum level).
|||| Short-term smoker: women who indicated that they smoked one or more 
cigarettes per day for less than 20 years.
¶¶ Long-term smoker: women who indicated that they smoked one or more 
cigarettes per day for 20 or more years.
## Proximal colon: cecum.
*** Serrated lesion: any serrated polyp including hyperplastic and sessile 
serrated adenoma.
††† Distal colon: sigmoid.
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and serrated lesions, including both hyperplastic polyps and sessile 
serrated adenomas). Separate calculations were done for each colonic 
location (proximal and distal colon) and gene. For data presentation, 
log-linear regression coefficients were back transformed and used 
to calculate rates of change in methylation per 10-year increase in 
age in respective lifestyle strata. The fold difference in the rate of 
change in methylation between two categories was defined as the 
methylation rate ratio (MRR). Full details and analyses are given in 
the Supplementary Materials (available online) and Supplementary 
Tables 2–4 (available online). The association between lifestyle factors 
and occurrence of polyps was examined by means of logistic multivar-
iable regression models adjusted for age, aspirin use, HRT use, BMI, 
and smoking but without age interaction (Supplementary Table  5, 
available online). Regression coefficients are expressed as odds ratios 
(ORs). Median regression analysis was conducted as supplementary 
analysis to evaluate the impact of extreme values on the results. The 
impact of methylation values below the detection limit was tested 
with tobit regression. Neither supplementary analysis changed the 
results, and thus they are not reported.
Genome-Wide DNA Methylation Analysis. The differential anal-
ysis of methylation data was performed on the M value (log2 ratios 
of methylated and unmethylated probes) using routines implemented 
in the R/Bioconductor limma package (26). Full details are given in 
the Supplementary Materials (available online). False-discovery rate 
(FDR)–adjusted P values for multiple comparison were calculated 
using the Benjamini and Hochberg approach. CpGs were considered 
statistically significantly differentially methylated with age when dis-
playing an FDR-adjusted P value less than .05. CpGs were considered 
statistically significantly hypermethylated in colorectal cancer vs nor-
mal when displaying FDR-adjusted P value less than .0001 and fold 
change difference in M values greater than 2. P values for the differ-
ence in median rate of DNA methylation change were calculated by 
Wilcoxon rank sum test. P values and ORs for overlap were calculated 
using Fisher exact test. Cancer relevance of identified age-related 
hypermethylation targets was addressed using the tumor-associated 
genes (TAG) database (27). Pathway analyses were performed with 
KEGGprofile in R/Bioconductor. All statistical tests were two-sided.
results
We investigated a cohort of 546 healthy women aged 50 to 80 years 
for relationships between gene promoter methylation in the colonic 
mucosa and the reported use of aspirin, reported HRT, BMI, and 
smoking (Table 1).
Age-Related DNA Methylation and Association With 
Lifestyle and Polyp Occurrence
We first measured hMLH1 and MGMT promoter methylation as per-
centage of methylated alleles by ln-qMSP in a total of 1092 normal 
biopsies obtained from cecum (proximal) and sigmoid (distal) colon. 
Log-linear multivariable regression analysis showed that methyla-
tion at the hMLH1 promoter statistically increased with age in the 
proximal colon (rate per 10 years of age = 2.1%; P < .001) (Figure 1A; 
Supplementary Table 2, available online). By contrast, the MGMT 
promoter did not show an overall age-dependent methylation change 
(Figure 1A; Supplementary Table 3, available online) unless lifestyle 
factors were taken into account (Figure 1B; Supplementary Table 3, 
available online); long-term aspirin use was associated with a more 
than 50% suppressed rate of methylation when compared with non-
use (proximal colon: MRR = 0.44, 95% CI = 0.27 to 0.70, P = .004; 
distal colon: MRR = 0.47, 95% CI = 0.31 to 0.73, P = .005), whereas 
HRT after the age of 50 years and long-term smoking slightly stimu-
lated MGMT methylation in the proximal colon (HRT: MRR = 1.63, 
95% CI = 1.05 to 2.53, P = .07; smoking: MRR = 1.51, 95% CI = 1.01 
to 2.26, P = .09). Notably, women with serrated lesions had a 48% 
higher rate of MGMT promoter methylation in the distal colon com-
pared with women with no polyps (MRR = 1.48; 95% CI = 1.12 to 
1.95; P = .02) (Figure 1C; Supplementary Table 4, available online), 
and the risk of serrated lesions was reduced in long-term aspirin 
users (OR = 0.36; 95% CI = 0.16 to 0.74; P = .03) but increased in 
long-term smokers (OR = 2.67; 95% CI = 1.72 to 4.15; P < .001) 
(Figure 1D; Supplementary Table 5, available online). No association 
with lifestyle and/or the occurrence of polyps was found for hMLH1 
promoter methylation (Supplementary Table 2, available online).
Next, we analyzed genome-wide DNA methylation in 178 
normal colon samples from our cohort (Illumina Infinium 
HumanMethylation27 BeadChip). We analyzed 20 025 promoter-
associated CpGs with multivariable regression adjusted for colonic 
location, aspirin use, HRT, BMI, and smoking and identified 1713 
CpGs gaining and 343 losing methylation with age; 219 CpGs 
acquired methylation exclusively in the proximal, and 416 acquired 
methylation exclusively in the distal colon (Figure  2A). When 
stratified for lifestyle factors, age-dependent hypermethylation was 
suppressed in aspirin users (43 CpGs in users vs 1355 in nonus-
ers) and/or in women reporting HRT (1 CpG in users vs 1377 in 
nonusers) but promoted in individuals with a high BMI (554 CpGs 
in high BMI vs 144 in normal BMI) (Figure 2B). Whereas aspirin 
use, HRT, and BMI modulated age-dependent DNA methylation 
changes along the entire colon, the effect of smoking was confined 
to the proximal colon (180 CpGs in smokers vs 39 in nonsmok-
ers) (Supplementary Figure  2, A  and B, available online). The 
median rate of age-dependent methylation change at hypermeth-
ylated CpGs (median rate = 1.6%; range = 0.07%–6.97%) was 56% 
higher in the distal colon than in the proximal colon (MRR = 1.56; 
P  =  9 × 10–18) (Figure  2C). The rate was 48% lower in aspirin 
users and 47% lower in women reporting HRT compared with 
non-users (aspirin: MRR = 0.52, P = 1 × 10–94; HRT: MRR = 0.53; 
P = 5 × 10–57) (Figure 2D), whereas a high BMI was associated with 
a 27% increased methylation rate in the distal colon (MRR = 1.27; 
P  = 5 × 10–9), and smoking was associated with a 400% increased 
rate in the proximal colon (MRR = 4.67; P = 1 × 10–28) but a 33% 
decreased rate in the distal colon (MRR  =  0.66; P  =  8 × 10–46) 
(Supplementary Figure 2, A and B, available online).
Examining potential interactions between these lifestyle effects, 
we found statistically significant overlaps between CpGs show-
ing suppression of age-related methylation by aspirin use or HRT 
(OR = 72; 95% CI = 62 to 83; P < 2 × 10–16) (Figure 2E) and, less 
pronounced, between CpGs showing BMI- or smoking-stimulated 
hypermethylation (OR  =  14; 95% CI  =  11 to 19; P  =  2 × 10–63). 
Although the methylation-retarding effect of aspirin use was appar-
ent in the entire study population, it appeared more effective in indi-
viduals with a high BMI (52%; MRR = 0.48; P = 2 × 10–31) compared 
with individuals with a normal BMI (22%; MRR = 0.78; P = .0001) 
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Figure  1. Association of human MutL homolog 1 (hMLH1) and O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation 
with lifestyle factors and polyps. A) hMLH1 and MGMT promoter meth-
ylation in proximal (cecum) and distal (sigmoid) colon as percentages 
of methylated alleles (PMAs) determined by locus normalized quanti-
tative methylation specific polymerase chain reaction (ln-qMSP). For 
presentation only, age is shown in two groups as indicated. Shown are 
median (lines) and mean (black circles) PMAs with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme 
values (gray lines). B) Association between age-dependent MGMT 
promoter methylation and lifestyle factors. Each point represents one 
biopsy. P values are derived from log-linear multivariable regression 
analysis (Supplementary Table 3, available online) representing signifi-
cance of the difference in two regression lines. C) Association of MGMT 
promoter methylation with the occurrence of polyps. Methylation rate 
ratios (MRRs) and P values are derived from log-linear multivariable 
regression (Supplementary Table 4, available online). D) Association of 
lifestyle parameters with the occurrence of polyps. Odds ratios (ORs) 
and P values are derived from logistic multivariable regression analy-
sis (Supplementary Table 5, available online). BMI = body mass index; 
CI = confidence interval; HRT = hormone replacement therapy. All statis-
tical tests were two-sided.
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Figure  2. Genome-wide DNA methylation and its association with 
lifestyle factors. A and B) Numbers of age-associated differentially 
methylated CpGs in all samples or when stratified by colon location 
(proximal [cecum] vs distal [sigmoid]) and lifestyle factors (aspirin: 
nonuser vs user [long-term]; hormone replacement therapy [HRT]: 
nonuser vs user [aged ≥50  years]; body mass index [BMI]: normal 
vs high [>25 kg/m2]; smoking: nonsmoker vs smoker [long-term]). 
Numbers of samples tested in each category are indicated at the bot-
tom of each bar. C and D) Ten-year rates of DNA methylation change 
for CpGs showing age-associated hypermethylation in all samples 
or when stratified by colon location and lifestyle factors. Shown are 
median (lines) and mean (black circles) rates with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme val-
ues (gray lines). P values according to the Wilcoxon rank sum test. 
E) Concordance of probes showing suppression of age-associated 
methylation by aspirin-use and HRT or promotion of age-associated 
methylation by a high BMI and long-term smoking. P values and odds 
ratios (ORs) according to the Fisher exact test. F) Enrichment of age-
associated differentially methylated sites marked by histone 3 lysine 27 
tri-methylation (H3K27me3) in human embryonic stem cells (hESCs). 
Barplots indicate percentages of age-associated hypermethylated 
(Age-hyperM) and hypomethylated (Age-hypoM) CpGs either marked 
by H3K27me3 (positive) or not (negative), or the enrichment of CpGs 
marked by H3K27me3 in lifestyle modulated age-related hypermeth-
ylation (bottom). Odds ratios and P values according to Fisher exact 
test. Density plots on the right show the rate of change in Age-hyperM 
and Age-hypoM probes at H3K27me3 positive (gray line) and negative 
(black, dashed line) CpGs. Dashed vertical lines indicate median rate 
of change per 10 years of age. PcG = polycomb group. All statistical 
tests were two-sided.
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or in smokers (79%; MRR = 0.21; P = 3 × 10–20) compared with non-
smokers (31%; MRR = 0.69; P = 2 × 10–84) (Supplementary Figure 2C, 
available online). HRT use retarded methylation in individuals with 
a high BMI only (70%; MRR = 0.30; P = 9 × 10–44), whereas its effect 
on smoking remained unclear because of limited statistical power.
Association of Lifestyle-Modulated DNA Methylation 
With Genomic Regions Disposed to Hypermethylation 
in Cancer
To investigate whether CpGs prone to age-dependent methylation 
are distinguished by specific genomic features, we classified array 
CpG probes with regard to coincidence of H3K27me3 in human 
embryonic stem cells. Regions surrounding age-hypermethylated 
CpGs were statistically significantly enriched for domains marked 
by H3K27me3 in stem cells compared with total H3K27me3 
marked CpGs on the array (OR = 4.84; 95% CI = 4 to 5; P = 4 × 10–175) 
(Figure  2F), and the median rate of age-dependent methylation 
was 53% higher at these sites compared with sites depleted for 
H3K27me3 (MRR  =  1.53; P  =  4 × 10–27). Aspirin use suppressed 
hypermethylation selectively at H3K27me3 marked sequences 
(user vs nonuser: OR  =  0.37; 95% CI  =  0.2 to 0.8; P  =  .004), 
whereas a high BMI promoted methylation at these sites (high vs 
normal BMI: OR = 1.6; 95% CI = 1.1 to 2.5; P = .02). The associa-
tion of hypermethylation with H3K27me3 modification was less in 
smokers (smoker vs nonsmokers: OR = 0.59; 95% CI = 0.5 to 0.8; 
P = .0003), indicating that smoking promotes methylation in CpG-
rich regions other than the typical polycomb targets.
Association of Lifestyle-Modulated DNA Methylation 
with CRC
To address the cancer relevance of these age- and lifestyle-
modulated DNA methylation changes in the healthy colon, 
we compared methylation data of 59 CRCs (female patients) 
included in a genome-wide methylation study (21) with those of 
our healthy mucosa samples. We identified 1709 CpGs statistically 
significantly hypermethylated and 1441 CpGs hypomethylated in 
the CRCs (Figure  3A). Half of the CpGs showing age-depend-
ent hypermethylation in the healthy mucosa (n  =  856 of 1713; 
OR = 20; 95% CI = 18 to 23; P  < 2 × 10–16) coincided with sites 
hypermethylated in CRC (Figure 3B; Age–Cancer). At these loci, 
the median rate of methylation gain per 10  years was doubled 
(MRR  =  2.21; P  =  2 × 10–76) compared with age-methylated sites 
only (Figure 3B; Age-only), and they were most highly enriched for 
polycomb regions (OR = 3.67; 95% CI = 3.0 to 4.5; P = 1 × 10–38). 
Age-hypermethylated CpGs also coincided partially with genes 
transcriptionally downregulated (n = 296 of 1287) (Figure 3C) in 
colonic adenomas (22), and 174 genes showed all features (ie, age- 
and CRC-dependent hypermethylation and transcriptional down-
regulation in adenomas) (Figure 3D).
Importantly, cancer-relevant methylation change in the normal 
colonic mucosa was influenced by lifestyle. A statistically significant 
fraction of promoters showing either aspirin- or HRT-suppressed 
methylation (aspirin: n = 549 of 1080, OR = 15, 95% CI = 13 to 
17, P  = 1 × 10–284; HRT: n = 612 of 996, OR = 25, 95% CI = 22 
to 30, P < 2.2 × 10–16) or BMI- or smoking-promoted methylation 
(high BMI: n = 209 of 510, OR = 6.8, 95% CI = 6 to 8, P = 9 × 10–76; 
smoking in proximal colon: n = 49 of 177, OR = 3.3, 95% CI = 2 
to 7, P = 1 × 10-10) in the aging colon coincided with sites hyper-
methylated in CRC (Figure  4A). These included genes control-
ling key aspects of carcinogenesis (Supplementary Figures 3–6, 
available online) such as cell cycle regulation (CDKN2A), DNA 
repair (MGMT), apoptosis (DAPK1), cell invasion (CDH1), and 
Wnt (WNT16) and RAS signaling (RASSF1) (2,28–30). Moreover, 
the rates of methylation change at promoters of established 
Figure  3. Enrichment of colorectal cancer (CRC)–associated hyper-
methylation in age-related methylated genes. A) Differences in DNA 
methylation between 59 CRC samples (21) of female patients and 178 
normal biopsies. Plotted are difference in log2-fold change (FC) in DNA 
methylation on the x-axis with false discovery rate (FDR)–adjusted P 
values (calculated by moderated t statistics; -1  × log10 scale) on the 
y-axis. CpGs statistically significantly hypermethylated in CRC are high-
lighted in red (n = 1709; FDR-adjusted P < .0001; FC > 2). B) Intersection 
between age-related hypermethylated CpGs in healthy mucosa and 
CpGs hypermethylated in tumor samples. Barplots indicate percent-
ages of CpGs marked by histone 3 lysine 27 tri-methylation (H3K27me3) 
in each intersection (Age-only Age–Cancer, Age-only, Cancer-only). The 
boxplot shows median rates of DNA methylation change per 10 years 
for age–tumor vs age-only hypermethylated loci. Shown are median 
(lines) and mean (black circles) rates with interquartile ranges (boxes), 
1.5 times the interquartile ranges (whiskers), and extreme values (gray 
lines). C) Intersection between 1287 age-related hypermethylated genes 
(n = 1713 CpGs) in the normal colon mucosa and genes downregulated 
(FDR-adjusted P ≤ .05) in colon adenomas (22). D) Intersection between 
genes statistically significantly hypermethylated over age in the nor-
mal colon mucosa, genes hypermethylated in CRC samples, and genes 
downregulated in colon adenomas. Odds ratios (ORs) and associated 
P values were calculated according to the Fisher exact test. P values 
for the difference in median rates of DNA methylation change were 
calculated according to the Wilcoxon rank sum test. All statistical tests 
were two-sided.
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tumor-associated genes (27) were statistically significantly reduced 
in aspirin users or in women reporting HRT compared with non-
users (aspirin: MRR = 0.53, P < .001; HRT: MRR = 0.54, P < .001) 
(Figure  4B) but increased in smokers vs nonsmokers or in indi-
viduals with high BMI vs normal BMI (smoking in proximal colon: 
MRR = 4.0, P < .001; high BMI: MRR = 1.57, P = .004).
Discussion
We report that lifestyle factors that are known modulators of CRC 
risk have widespread effects on the stability of gene promoter 
methylation in the aging colonic mucosa. We found age-associated 
DNA hypermethylation to be suppressed by regular aspirin use 
and HRT use but accelerated by long-term smoking and a high 
BMI, which is concordant with the effects of these factors on CRC 
risk. Statistically significant subsets of affected promoters were 
associated with genes controlling key aspects of carcinogenesis and 
with chromatin features known to predispose to hypermethylation 
in cancer, accentuating the cancer relevance of the lifestyle-mod-
ulated DNA methylation change in the normal colon. These find-
ings provide an important resource for understanding the interplay 
between lifestyle exposure and aging in the modulation of epige-
netic (in)stability in colonic epithelial cells and, thereby, in the evo-
lution of CRC methylomes.
Our data extend the well-established relationships between 
aging and gene promoter hypermethylation (9,31,32) by providing 
a functional link to cancer. Comparing genome-wide methylation 
data of CRC (21) with those of normal aging mucosa allowed us to 
discriminate between age-only, cancer-only and age–cancer hyper-
methylation. Importantly, the rate of methylation change at age–
cancer hypermethylated sites was statistically significantly higher 
than at loci showing age-only methylation, and aspirin use and 
Figure 4. Modulation of cancer-associated hypermethylation by lifestyle 
factors. A) Concordance between genes showing modulation of age-
associated methylation by lifestyle parameters and hypermethylation in 
colorectal cancer (CRC). Enrichment in each category is calculated over 
the percentage of 11 872 genes (n = 20 025 CpGs) present on the Illumina 
array (Total). Odds ratios (ORs) and P values were calculated according 
to the Fisher exact test. n = number of genes. B) Median rates of DNA 
methylation on 664 annotated tumor-associated genes (TAG database) 
(27). n = number of tumor-associated genes hypermethylated in each 
category. P values are calculated by Wilcoxon rank sum test. Shown are 
median (lines) and mean (black circles) rates with interquartile ranges 
(boxes), 1.5 times the interquartile ranges (whiskers), and extreme val-
ues (gray lines). C) Mode for the modulation of CRC risk by lifestyle 
factors (41). Inherent DNA methylation instability generates epigenetic 
mosaicism (gray cells) in the aging colonic epithelium. Some methyla-
tion changes will affect transcription of genes controlling carcinogen-
esis, eventually contributing to the evolution of premalignant (gray cell 
cluster) and cancer cells (red cell cluster). Lifestyle factors are capable 
of negatively (blue arrow) or positively (green arrow) influencing pro-
gressive age-related methylation change, thereby connecting lifestyle 
with cancer risk. BMI = body mass index; HRT = hormone replacement 
therapy; OR = odds ratio. All statistical tests were two-sided.
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HRT use suppressed whereas high BMI and smoking promoted 
methylation in a large fraction of these promoters. The identifica-
tion of this specific subgroup of gene promoters, displaying age-
associated and cancer-associated hypermethylation modulated by 
lifestyle factors, is important for several reasons. First, the targets 
provide insight into molecular pathogenesis of CRC and how 
lifestyle factors may exert their effects on CRC risk. Second, age-
associated hypermethylation at such targets in the normal colonic 
mucosa implies a risk for CRC. Hence, age–cancer hypermethyl-
ated CpGs may serve as biomarkers for risk prediction and dis-
ease progression because their methylation can be monitored in 
the healthy mucosa. Third, unlike genetic mutations, epigenetic 
alterations are reversible and the identification of gene promoters 
at which hypermethylation can be modulated by lifestyle will help 
develop tailored methylation and thus cancer-preventive strategies. 
Future investigations will thus have to be directed toward estab-
lishing biomarker panels with methylation thresholds predicting 
cancer risk in healthy individuals and to evaluate the clinical poten-
tial of methylation-suppressive medication.
Numerous studies have shown that aspirin use is associated with 
a lower incidence of colonic neoplasia, metastatic CRC, and death 
due to CRC (33–36). Although the genetic makeup of a tumor is 
likely to play a role in this context (37), our methylation profiling 
of the normal colonic mucosa adds to the understanding of this 
cancer protective effect, showing that regular aspirin use stabilizes 
DNA methylation at promoters of genes controlling critical cancer 
pathways. This is likely to retard carcinogenesis at different stages, 
including metastasis, in the colon and other tissues. This insight 
will thus be instrumental in identifying both patients and healthy 
individuals who will benefit from aspirin use.
Our study has several strengths. First, we collected normal 
mucosa samples from an unselected screening cohort, providing 
for an unbiased analysis of methylation profiles. Second, the age-
related and lifestyle-modulated methylation changes observed in 
the promoters of the two DNA-repair and tumor-suppressor genes 
hMLH1 and MGMT are an important proof of concept because the 
pathogenic consequence of their epigenetic silencing is well known. 
Third, the comparison of our genome-wide methylation data in 
normal mucosa of a female screening cohort with those of women 
with CRC enabled us not only to exclude sex-associated methyla-
tion variance but also to identify the gene promoters at which age-
related hypermethylation is relevant for CRC development.
There are also limitations to our study. Residual confounding 
by measured or unmeasured additional factors cannot be excluded. 
To limit biological variation, we investigated only women and, 
therefore, our findings will have to be validated by independent 
studies including men. Genome-wide methylation array is largely 
restricted to CpG islands, thereby limiting the detection of meth-
ylation globally.
We conclude that the aging colonic mucosa undergoes changes 
in gene promoter methylation with rates modulated by lifestyle. 
The highly variable methylation rates at individual CpGs are con-
sistent with an underlying inherent instability of DNA methyla-
tion rather than an outgrowth of subpopulations of tissue cells; a 
concept supported by many other studies (38–40). We propose that 
this epigenetic instability contributes to the aging of the colonic 
epithelium (41), generating opportunities for the evolution of early 
cancer-initiating cells (Figure  4C) showing patterns of aberrant 
DNA methylation typically observed in malignant tissues (2). The 
finding that lifestyle factors specifically modulate the rate of the 
underlying DNA methylation change provides a novel paradigm 
for how the environment modulates cancer risk.
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